{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:41:20Z","timestamp":1791103280425,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/bor.0b013e32835b133a","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T06:47:18Z","timestamp":1351666038000},"page":"3-9","source":"Crossref","is-referenced-by-count":89,"title":["New treatment strategies in large-vessel vasculitis"],"prefix":"10.1097","volume":"25","author":[{"given":"Sebastian","family":"Unizony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica.","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11882-008-0052-4","article-title":"Neuro-ophthalmic complications in giant cell arteritis.","volume":"8","author":"Borg","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/art.23315","article-title":"Development of aortic aneurysmdilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients.","volume":"59","author":"Garcia-Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.33343","article-title":"Giant cell aortitis of the ascending aorta without signs or symptoms of systemic vasculitis is associated with elevated risk of distal aortic events.","volume":"64","author":"Wang","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis.","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/BOR.0b013e32834dc392","article-title":"Biologic treatment of large-vessel vasculitides.","volume":"24","author":"Schafer","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/BOR.0b013e32833ee946","article-title":"IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis.","volume":"23","author":"Weyand","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/art.34327","article-title":"IL-21 modulates Th1 and Th17 responses in giant cell arteritis.","volume":"64","author":"Terrier","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine.","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.4049\/jimmunol.175.6.3463","article-title":"Directing transition from innate to acquired immunity: defining a role for IL-6.","volume":"175","author":"Jones","year":"2005","journal-title":"J Immunol"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann Intern Med"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0198-8859(94)90096-5","article-title":"Production of interleukin 6 by granulomas of giant cell arteritis.","volume":"39","author":"Emilie","year":"1994","journal-title":"Hum Immunol"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/acr.20043","article-title":"Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.","volume":"62","author":"Garcia-Martinez","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7","article-title":"Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.","volume":"43","author":"Weyand","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/art.24126","article-title":"Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.","volume":"58","author":"Fujimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1073\/pnas.0802218105","article-title":"IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.","volume":"105","author":"Serada","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"18460","DOI":"10.1073\/pnas.0809850105","article-title":"IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3 regulatory T cells.","volume":"105","author":"Korn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis.","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology"},{"key":"R22-4-20210128","first-page":"w13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series.","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3899\/jrheum.110496","article-title":"Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis.","volume":"38","author":"Sciascia","year":"2011","journal-title":"J Rheumatol"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/ard.2010.149351","article-title":"Antiinterleukin 6 receptor therapy as rescue treatment for giant cell arteritis.","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jbspin.2011.11.008","article-title":"Efficacy of tocilizumab in refractory giant cell arteritis.","volume":"79","author":"Vinit","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10067-012-2007-3","article-title":"Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab.","volume":"31","author":"Besada","year":"2012","journal-title":"Clin Rheum"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis.","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0889-857X(21)00484-1","article-title":"Takayasus arteritis.","volume":"21","author":"Kerr","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00002281-199701000-00003","article-title":"Differences in clinical presentation and outcome in different countries for Takayasus arteritis.","volume":"9","author":"Numano","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.1780370420","article-title":"Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.","volume":"37","author":"Hoffman","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.22404","article-title":"Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients.","volume":"56","author":"Maksimowicz-McKinnon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10067-009-1333-6","article-title":"Mycophenolate mofetil in Takayasus arteritis.","volume":"29","author":"Goel","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","article-title":"Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.","volume":"45","author":"Tanaka","year":"2006","journal-title":"Intern Med"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Antitumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/rheumatology\/ker380","article-title":"Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study.","volume":"51","author":"Mekinian","year":"2012","journal-title":"Rheumatology"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","article-title":"Anti TNF-alpha in refractory Takayasus arteritis: cases series and review of the literature.","volume":"11","author":"Comarmond","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jvs.2010.06.173","article-title":"Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis.","volume":"53","author":"Wang","year":"2011","journal-title":"J Vasc Surg"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/ard.2011.153007","article-title":"Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.","volume":"71","author":"Hoyer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0967-2109(99)00100-3","article-title":"Immunophenotypic analysis of the aortic wall in Takayasus arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions.","volume":"8","author":"Inder","year":"2000","journal-title":"Cardiovasc Surg"},{"key":"R42-4-20210128","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nri2729","article-title":"Effector and regulatory B cells: modulators of CD4() T cell immunity.","volume":"10","author":"Lund","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","article-title":"From T to B and back again: positive feedback in systemic autoimmune disease.","volume":"1","author":"Shlomchik","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1084\/jem.20110978","article-title":"A small CD11b() human B1 cell subpopulation stimulates T cells and is expanded in lupus.","volume":"208","author":"Griffin","year":"2011","journal-title":"J Exp Med"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrrheum.2010.140","article-title":"Regulatory B cells in autoimmunity: developments and controversies.","volume":"6","author":"Mauri","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R47-4-20210128","first-page":"124","article-title":"Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases Clin Rev Allergy I","volume":"34","author":"Galarza","year":"2008","journal-title":"mmunol"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/01.CIR.93.10.1788","article-title":"Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasus arteritis.","volume":"93","author":"Seko","year":"1996","journal-title":"Circulation"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","article-title":"Serum cytokine profiles and their correlations with disease activity in Takayasus arteritis.","volume":"45","author":"Park","year":"2006","journal-title":"Rheumatology"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody.","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R51-4-20210128","first-page":"S98","article-title":"One-year clinical and radiological evolution of a patient with refractory Takayasus arteritis under treatment with tocilizumab.","volume":"30","author":"Bredemeier","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R52-4-20210128","first-page":"S90","article-title":"Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers.","volume":"30","author":"Salvarani","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03009742.2011.633553","article-title":"Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.","volume":"41","author":"de Souza","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/BOR.0b013e3283412f7c","article-title":"Aortitis, periaortitis, and retroperitoneal fibrosis as manifestations of IgG4-related systemic disease.","volume":"23","author":"Stone","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: Lessons from 10 consecutive patients.","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine"},{"key":"R56-4-20210128","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/ker451","article-title":"Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-alpha failure in a patient with relapsing polychondritis complicated by aortitis.","volume":"51","author":"Narshi","year":"2012","journal-title":"Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e32835b133a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T18:36:52Z","timestamp":1643567812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201301000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32835b133a","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}